DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20160510

Correlation of non alcoholic fatty liver disease in patients of coronary artery disease

Khwaja Saifullah Zafar, N. A. Wafai, S. F. Haque

Abstract


Background: In NAFLD, increase in factor VIII and a reduction of protein C leads to the progression from steatosis to cirrhosi. The aim was to study the correlation of NAFLD with other associated risk factors of CAD.

Methods: A total number of 100 patients of coronary artery disease were assessed for presence of NAFLD, dyslipidemia, metabolic syndrome & diabetes by various laboratory tests.

Results: 46% of the CAD patients were found to have NAFLD. 69.6% patients of NAFLD were in the age group of 40-60 years. 21.7% were above 60 years. 91.1% of NAFLD patients were males. Half of the NAFLD patients were diabetic. 21.7% of NAFLD patients were found to have a total cholesterol level >200. Triglyceride level was also high among these patients (58.7%). All the NAFLD patients had LDL <100. 52.2% of them had metabolic syndrome.

Conclusions: The study showed a direct correlation between NAFLD & CAD. Metabolic syndrome, diabetes, increased total cholesterol & triglyceride level were also associated with increased risk for CAD. However LDL level was not found to be associated with NAFLD risk.


Keywords


Coronary artery disease, Fatty liver, Non-alcoholic risk factor

Full Text:

PDF

References


Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic expeience with a hitherto unnamed disease. Mayo Clin Proc. 1980;55(7):434-8.

Guy CD, Suzuki A, Zdanowicz M, Abdelmalek MF, Burchette J, Unalp A. Hedgehog pathway activation parallels histologic severity of injury and fibrosis in human non-alcoholic fatty liver disease. Hepatology. 2012;55(6):1711-21.

Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med. 2000;132(2):112-7.

Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non- alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J. 2012;33(10):1190-1200.

Bellentani S, Marino M. Epidemiology and natural history of non- alcoholic fatty liver disease(NAFLD). Ann Hepatol. 2009;1:S4-8.

Chow WC, Tai ES, Lian SC, Tan CK, Sng I, Ng HS. Significant non-alcoholic fatty liver disease is found in non-diabetic, pre-obese Chinese in Singapore. Singapore Med J. 2007;48(8):752-7.

Park JW, Jeong G, Kim SJ, Kim MK, Park SM. Predictors reflecting the pathologic severity of non-alcoholic fatty liver disease: comprehensive study of clinical and immunohistochemical findings in younger Asian patients. J Gastroenterol Hepatol. 2007;22(4):491-7.

Duseja A, Das A, Das R, Dhiman RK, Chwla Y, Bhansali A. The clinicopathological profile of Indian patients with non-alcoholic fatty liver disease (NAFLD) is different from that of the west. Dig Dis Sci. 2007;52(9):2368-74.

Kumar V, Abbas AK, Fausto N, Mitchell RN. Robbins basic pathology. 2007;8:379-420.

Gastaldelli A, Kozakova M, Hojiund K, Fvvbjerg A. Fatty liver is associated with insulin resistance,risk of coronary heart disease and early atherosclerosis in a large European population. Hepatology. 2009;49(5):1537-44.

Prashanth M, Ganesh HK, Vima MV. John M, Bandgar T, Joshi SR, et al. Prevalence of non alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Journal Assoc Physicians India. 2009;57:205-10.

Kwon YM, Oh SW, Hwang SS, Lee C, Kwon H, Chung GE. Association of non alcoholic fatty liver disease with components of metabolic syndrome according to Body Mass Index in Korean adults. Am J Gastroenterol. 2012;107(12):1852-8.

Souza MR, Diniz Mde F, Medeiros- Filho JE, Araujo MS. Metabolic syndrome and risk factors for nonalcoholic fatty liver disease. Arq Gasteroenterol. 2012;49(1):89-96.

Kalra. Study of prevalence of Non alcoholic fatty liver disease in type 2 Diabetes Mellitus patients in India. J Assoc Physicians India. 2013;61(7):44-53.

Sung KC, Wild SH, Kwag HJ, Byrne CD. Fatty liver, insulin resistance and features of metabolic syndrome: relationship with coronary artery calcium in 10,153 people. Diabetes care. 2012;35(11):2359-64.

Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with Non Alcoholic Fatty Liver Disease. N Engl J Med. 2010;363(14):1341-50.

Marcin. Non alcoholic fatty liver disease.Best Prac Res Clin Gastroenterol. 2010;24(5):695-708.

Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary artery disease in the United States. Hepatology. 2006;43(5):1145-51.

Cheung O, Kapoor A, Puri P, Sistrun S, Luketic VA, Sargeant CC, et al. The impact of fat distribution on the severity of non alcoholic fatty liver disease and metabolic syndrome. Hepatology. 2007;46(4):1091-100.

Targher G, Arcaro G. Non Alcoholic Fatty Liver Disease and increased risk of cardiovascular disease. Atherosclerosis. 2007;191(2);235-40.

Pacifico L, Cantisani V, Ricci P, Osborn JF, Anania C, Ferrara E, et al. Non alcoholic fatty liver disease and carotid atherosclerosis in children. Pediatr Res. 2008;63(4);423-27.

Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Non Alcoholic Fatty Liver Disease: A spectrum of clinical and pathological severity. Gastroenterology. 1999;116(6):1413-9.